Our Take
The study found a replication crisis: fewer than half of gene expression changes detected in one cohort replicated in the second, yet the findings that did hold up point clearly to epithelial cells and specific macrophages as actionable targets for existing JAK inhibitors.
Why it matters
Crohn's disease affects over half a million people in the UK alone, and 15% require surgery within five years because current therapies fail. A publicly available cellular map with replicable findings gives drug developers a sharper target list than before.
Do this week
Drug development teams: cross-reference your Crohn's candidate targets against the IBDverse dataset (now open to researchers) this quarter to assess overlap with the replicated epithelial and ITGA4+ macrophage signatures.
Over 1 Million Gut Cells Sequenced to Find Crohn's Inflammation Drivers
Researchers at the Wellcome Sanger Institute, Cambridge University Hospitals NHS Foundation Trust, and Open Targets analyzed single-cell RNA sequencing data from 111 Crohn's disease patients with terminal ileitis and 232 healthy controls. They sequenced more than 1.18 million individual cells from small intestine biopsies to map gene activity changes across over 50 cell types.
The resulting dataset, called IBDverse, is now available as an open resource for researchers worldwide. The team published their primary findings in Nature Genetics under the title "Single-cell RNA sequencing of terminal ileal biopsies identifies signatures of Crohn's disease pathogenesis," with a complementary study in Nature.
Two key findings emerged. First, researchers identified a population of macrophages with high expression of the gene ITGA4 that act as primary drivers of inflammation through the JAK/STAT signaling pathway, a pathway already targeted by existing JAK inhibitor drugs used to treat inflammatory bowel disease. Second, they discovered what they call a "molecular scar" in the gut lining: even after visible inflammation had healed, genes involved in immune signaling remained switched on in the gut's stem cells (epithelial progenitor cells).
"We uncovered epithelial changes marked by interferon-driven upregulation of major histocompatibility complex class I molecules that persisted in progenitor cells after macroscopic inflammation resolution," the investigators wrote in their Nature Genetics paper.
Replication Data Matters More Than Scale Alone
The headline count of 1.1 million cells is noteworthy, but the study's most important message came from co-senior author Carl Anderson: "What makes this study different is that we designed replication in from the start and found that even with hundreds of patients and standardized protocols, fewer than half of the gene expression changes we detected in one cohort replicated in the other."
This is sobering for the field. It means that large single-cell datasets, while valuable, can obscure noise and technical variation. What matters is which findings hold up across independent cohorts. In this case, the epithelial scar and the ITGA4+ macrophage signature were among the findings that replicated.
Crohn's disease remains poorly understood at the cellular level despite affecting over 500,000 people in the UK. Current therapies targeting immune cells have helped some patients, but 15% of newly diagnosed patients require surgery within five years. The persistent molecular signature in healed tissue may explain why inflammation returns or why some patients are treatment-resistant.
The open release of IBDverse gives drug developers a reference atlas to validate and prioritize targets before investing in preclinical or clinical work. It also provides a template for similar single-cell studies of other organ-based diseases like eczema and asthma.
Use IBDverse to Validate Crohn's Targets Before Advancing
Teams working on Crohn's therapeutics should cross-check candidate targets against the IBDverse data, paying particular attention to genes and cell types that showed replication across cohorts. The ITGA4+ macrophage population and the interferon-signaling signature in epithelial cells are now experimentally validated starting points.
For academic researchers, IBDverse is openly available for hypothesis generation. The dataset is large enough to detect rare cell populations and cell-state transitions that may not show up in smaller studies. Be aware, however, that findings from your own analysis should be treated as hypothesis-generating until validated in an independent cohort or patient population.